Erratum: Enteral metronidazole for the prevention of graf-versus-host disease in pediatric marrow transplant recipients: Results of a pilot study (Bone Marrow Transplantation (2004) vol. 33 (1235-1239) 10.1038/sj.bmt.1704474);Enteral metronidazole for the prevention of graft versus host disease in pediatric marrow transplant recipients: Results of a pilot study

Bone Marrow Transplantation

Volumn 33, Issue 12, 2004, Pages 1235-1239

  Guthery, Stephen L ^a   Heubi, J E ^b   Filipovich, A ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Div Pediat Gastroenterol Nutr   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Alternative donor; Graft versus host disease; Intestinal flora; Metronidazole; Pediatrics; Prevention

Indexed keywords

CYCLOSPORIN; GABAPENTIN; METHOTREXATE; METRONIDAZOLE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CENTER; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC FEEDING; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEG EDEMA; LIVING DONOR; MALE; NASOGASTRIC TUBE; NAUSEA; NOSE FEEDING; PARESTHESIA; PATIENT REFERRAL; PERIPHERAL NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; PROBABILITY; RECIPIENT; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; UMBILICAL CORD BLOOD; VOMITING;

EID: 3242659159     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705076     Document Type: Erratum

References (18)

1. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/ severe acute graft- versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
2. Filipovich AH, Vallera DA, Youle RJ et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. Transplantation 1987; 44: 62-69.
3. Roy J, McGlave PB, Filipovich AH et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77-82.
4. Weisdorf D, Filipovich A, McGlave P et al. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Bone Marrow Transplant 1993; 12: 531-536.
5. Bekkum DWv, Roodenburg J, Heidt PJ, Waaij Dvd. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401-404.
6. Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992; 80: 2668-2676.
7. Beelen DW, Elmaagacli A, Muller KD et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267-3275.
8. Grove D, Mahmoud A, Warren K. Suppression of cell-mediated immunity by metronidazole. Int Archs Allergy Appl Immun 1977; 54: 422-427.
9. Tanga MR, Antani JA, Kabade SS. Clinical evaluation of metronidazole as an anti-inflammatory agent. Int Surg 1975; 60: 75-76.
10. Storb R, Prentice RL, Buckner CD et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302-307.
11. Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075.
12. Ursing B, Alm T, Barany F et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 550-562.
13. Freston J. Looking for hepatotoxicity, working up patients, and assessing causality. In: Drug-Induced Liver Injury: A National and Global Problem 12-13 February 2001, Westfields Conference Center, Chantilly, VA; 2001; Westfields Conference Center, Chantilly, VA: Food and Drug Administration, 2001.
14. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
15. Hill GR, Krenger W, Ferrara JL. The role of cytokines in acute graft-versus-host disease. Cytokines Cell Mol Ther 1997; 3: 257-266.
16. Ganrot-Norlin K, Stalhandske T, Karlstrom R. Lack of antiinflammatory activity of metronidazole. Acta Pharmacol Toxicol (Copenh) 1981; 49: 130-133.
17. Duffy LF, Daum F, Fisher SE et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88: 681-684.
18. Bradley WG, Karlsson IJ, Rassol CG. Metronidazole neuropathy. Br Med J 1977; 2: 610-611.